ECU
ACAD icon

Eisler Capital (US)’s Acadia Pharmaceuticals ACAD Stock Holding History

Eisler Capital (US)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,340
Closed -$818K – 473
2024
Q2 		$818K Buy
50,340
+10,992
+28% +$177K 0.01% 508
2024
Q1 		$728K Buy
+39,348
New +$975K 0.02% 384

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Eisler Capital (US)'s ACAD Position: Q3 2024 in Review

Eisler Capital (US) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 50,340 shares — an estimated $818K sold.

Eisler Capital (US) first reported a position in ACAD in Q1 2024 and held it in 2 quarters. The position peaked at $818K in Q2 2024. 257 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Eisler Capital (US) reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 50,340 Acadia Pharmaceuticals shares in Q3 2024, an estimated $818K.
  • Eisler Capital (US) first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s Acadia Pharmaceuticals position peaked at $818K in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.